Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTE-451 in moderate to severe plaque psoriasis
NCT03832738Phase 2Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of JTE-451 in plaque psoriasis (3 arms), sponsored by Akros Pharma Inc. Primary endpoint: Proportion of subjects achieving >=75% improvement in Psoriasis Area and Severity Index at 16 weeks. Started Jan 2019; status: completed.
02
Drugs
JTE-451
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03832738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832738.